



eISSN 2282-2054

<https://www.pagepressjournals.org/index.php/ecj/index>

**Publisher's Disclaimer.** E-publishing ahead of print is increasingly important for the rapid dissemination of science. The **Early Access** service lets users access peer-reviewed articles well before print / regular issue publication, significantly reducing the time it takes for critical findings to reach the research community.

These articles are searchable and citable by their DOI (Digital Object Identifier).

The **Emergency Care Journal** is, therefore, e-publishing PDF files of an early version of manuscripts that undergone a regular peer review and have been accepted for publication, but have not been through the typesetting, pagination and proofreading processes, which may lead to differences between this version and the final one.

The final version of the manuscript will then appear on a regular issue of the journal.

E-publishing of this PDF file has been approved by the authors.

Emerg Care J 2024 [Online ahead of print]

*To cite this Article:*

Rienzo P, Poggiali E. **That purplish huge hole on the chest wall.** *Emerg Care J* doi: 10.4081/ecj.2024.12790

 ©The Author(s), 2024

Licensee [PAGEPress](#), Italy

Note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

## **That purplish huge hole on the chest wall**

Paola Rienzo,<sup>1</sup> Erika Poggiali<sup>2</sup>

<sup>1</sup>Emergency Department, San Raffaele Hospital IRCCS, Milan; <sup>2</sup>Emergency Medicine Unit, Fatebenefratelli Hospital, ASST Fatebenefratelli Sacco, Milan, Italy

**Correspondence:** Erika Poggiali, Emergency Medicine Unit, Fatebenefratelli Hospital, ASST Fatebenefratelli Sacco, Milan, Italy.

E-mail: [poggiali.erika@gmail.com](mailto:poggiali.erika@gmail.com)

**Key words:** Pyoderma Gangrenosum, skin diseases, ulcer, skin lesions, thoracic surgery, VATS.

**Contributions:** all the authors approved the final version and equally contributed to the work.

**Conflicts of interest:** EP is a member of the editorial board of ECJ. This work was not supported by any grant.

**Availability of data and materials:** all data underlying the findings are fully available upon reasonable request to the Corresponding Author.

**Ethics approval and consent to participate:** as this was a descriptive case report and data was collected without patient identifiers, ethics approval was not required under our hospital's Institutional Review Board guidelines.

**Informed consent:** the patient provided consent for access to medical records at the time of admission.



### **Descriptive legend**

A 54-year-old woman presented to our emergency department two months after the removal by Video-Assisted Thoracoscopic Surgery (VATS) of her middle lung lobe affected by severe inflammation and fibrosis. She was experiencing pain from a large ulcer (diameter 13 cm) starting

from the surgical scar. She suffered from Calcinosis, Raynaud phenomenon, Esophageal dysmotility, Sclerodactyly, and Telangiectasia (CREST) syndrome, and hypothyroidism. The laboratory results showed White Blood Cell count (WBC) 13,600/mm<sup>3</sup> (N 76%), C-Reactive Protein (CRP) 12 mg/L (nv<6), and Erythrocyte Sedimentation Rate (ESR) 86 mm/h (nv<20). Repeat skin swabs were always negative. Skin biopsy documented granulocyte infiltration in the dermis-hypodermis with tissue necrosis. For three weeks, the patient was treated with methylprednisolone 1 mg/Kg IV and colchicine 0.5 mg q12h orally. In the absence of a good response, oral cyclosporine 75 mg q12h was added. The ulcer gradually improved within a week. The pain was successfully treated with paracetamol 1 gr q8h IV.

**Question:** Given the patient history and the clinical presentation, what is the most likely diagnosis?

- 1) Pyogenic granuloma
- 2) Necrotizing fasciitis
- 3) Pyoderma gangrenosum
- 4) Martorell ulcer

**Answer:** The right answer is Pyoderma Gangrenosum (PG). PG is a rare ulcerative disorder that belongs to the category of neutrophilic dermatoses.<sup>1</sup> Despite its name, PG is not caused by infection or gangrene. The etiology is unknown. In 70% of patients, PG is associated with a systemic condition, including ulcerative colitis (5-12%), Crohn's disease (1-2%), solid tumours, and haematologic malignancies (20%).<sup>2</sup> The most common age of presentation is 30-50 years. Women are more commonly affected.<sup>1</sup> The pathogenesis is not fully understood.<sup>3</sup> PG is a diagnosis of exclusion both clinically and histologically. There are no specific lab markers.<sup>1</sup> Lesions are often initiated by minor trauma or scarring, and start with a small, red bump on the skin. Necrotic ulcers can develop rapidly over a period of 4-8 weeks. They usually exceed 10 cm in diameter and present with a purplish, undermined edge and surrounding erythema. Pathergy is the most important feature of PG. PG can affect any anatomical or surgical site. The skin over the tibia is a classic site. The head, oral cavity, and neck are rarely involved.<sup>4</sup> The differential diagnosis includes mycobacterial and deep fungal infections. Martorell ulcers and necrotizing fasciitis must be always excluded.<sup>5</sup> The treatment requires an interprofessional approach. The underlying systemic disease must be always treated.<sup>6</sup> Wound care and pain control are key features in the treatment. Debridement must be performed very cautiously because of the association with pathergy.<sup>7</sup> Systemic corticosteroids are the first-line therapy. Anti-TNF-alpha drugs such as etanercept and adalimumab have been used successfully.<sup>8</sup> The prognosis is generally good, but relapses are common.

## References

1. Schmieder SJ, Krishnamurthy K. Pyoderma Gangrenosum. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK482223/>
2. Ashchyan HJ, Butler DC, Nelson CA, et al. The association of age with clinical presentation and comorbidities of pyoderma gangrenosum. *JAMA Dermatol.* 2018;154:409-13. Erratum in: *JAMA Dermatol.* 2018;154:630.

3. Braswell SF, Kostopoulos TC, Ortega-Loayza AG. Pathophysiology of pyoderma gangrenosum (pg): an updated review. *J Am Acad Dermatol.* 2015;73:691-8.
4. Bissonnette C, Kauzman A, Mainville GN. Oral pyoderma gangrenosum: diagnosis, treatment and challenges: a systematic review. *Head Neck Pathol.* 2017;11:427-41.
5. Vaysse-Vic M, Mathieu PA, Charissoux A, et al. Pyoderma gangrenosum or necrotising fasciitis? Diagnostic and therapeutic wanderings. *Orthop Traumatol Surg Res.* 2017;103:615-7.
6. Kaffenberger BH, Hinton A, Krishna SG. The impact of underlying disease state on outcomes in patients with pyoderma gangrenosum: a national survey. *J Am Acad Dermatol.* 2018;79:659-63.e2.
7. Pichler M, Larcher L, Holzer M, et al. Surgical treatment of pyoderma gangrenosum with negative pressure wound therapy and split thickness skin grafting under adequate immunosuppression is a valuable treatment option: Case series of 15 patients. *J Am Acad Dermatol.* 2016;74:760-5.
8. Reichrath J, Bens G, Bonowitz A, Tilgen W. Treatment recommendations for pyoderma gangrenosum: an evidence based review of the literature based on more than 350 patients. *J Am Acad Dermatol.* 2005;53:273-83.

**Submitted: 5 July 2024**

**Accepted: 30 July 2024**

**Early access: 23 August 2024**